Skip to content

Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With STEMI

Prospective Observational Clinical Study:The Impact of Early rhBNP on Myocardial Remodeling and Reperfusion in Patients With ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04033861
Enrollment
352
Registered
2019-07-26
Start date
2019-06-19
Completion date
2023-12-01
Last updated
2023-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Segment Elevated Myocardial Infarction

Keywords

ST Segment Elevated Myocardial Infarction, rhBNP, cardiac magnetic resonance, Microvascular disease, ventricular remodeling

Brief summary

The study intends to evaluate the efficacy of early rhBNP on myocardial remodeling and reperfusion in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention

Detailed description

As prospectively observational study,it brings anterior acute myocardial infarct patients from 2018 JAN. to 2019 JAN, whose predefined time between symptom onset and percutaneous is not more than 12 hours. The door-to-balloon time, present to balloon time and first medical contact-to-balloon time will be documented. ECG in FMC and 90min after PCI also will be record. Patients assigned to the rhBNP group will receive intravenous rhBNP before PCI,and the variety of heart rate and blood pressure will be record. Routinely evaluation of corrected TIMI frame counting(CTFC), TIMI myocardial perfusion frame counting and TIMI myocardial perfusion grade(TMPG).Blood tests including BNP, CK-MB and CRP are measured at admission and6, 12, 24, 48 hours after PCI. Both Cardiovascular magnetic imaging and echocardiography will be applied in Day 30 and 12 months. The composite endpoint is incidence of all-cause mortality, reinfarct, stroke and target vessel revascularization at hospitalization and follow-up. Principally patients are prevented from any drug affecting microcirculation (GPIIb/IIa receptor agonist, vascular dilation drug, etc.), otherwise it is necessary, which should be documented.

Interventions

DRUGrhBNP

rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.

DRUGControl

saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.

Sponsors

Shanghai 6th People's Hospital
CollaboratorOTHER
Shanghai Minhang Central Hospital
CollaboratorOTHER
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
CollaboratorOTHER
Suqian First Hospital
CollaboratorOTHER
RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Patients are eligible for enrollment if they are suspected as anterior myocardial infarct (anterior myocardial infarct is defined as persistent chest pain for 30 mins at least, with ST-segment elevation of at least 0.2 mV in two or more contiguous precordial leads) within 12 hours after onsets of symptom, and no contraindication for rhBNP. The coronary angiography (CAG) proves left anterior descending (LAD) as culprit vessel, which was totally or nearly occlusion with TIMI 0-1 grade and resulted in TIMI 3 grade after PCI. Exclusive criteria: 1. Killips grade III-IV. 2. unstable hemodynamic; with A-V block or atrial fibrillation; 3. Contraindication of magnetic resonance, such as history of metal, ICD or paceman implant; 4. history of myocardial infarct; 5. pregnancy or breeding; 6. combined with other serious diseases: severe renal dysfunction (creatinine clearance\<30ml/min;), liver failure, neutropenia, thrombocytopenia, acute pancreatitis; 7. life expectancy≤12 months

Design outcomes

Primary

MeasureTime frameDescription
Compound endpoints of epicardium and endocardium perfusion90min after infarct related artery revascularizationBoth the TIMI and TMPG score reach 3 immediately after PCI, besides ST resolution≥70% at 90min after PCI.

Secondary

MeasureTime frameDescription
ST-segment Resolution90 mins after PCIResolution of the initial sum of ST-segment elevation ≥ 70%
Wall motion score index (WMSI) and LVEF by echocardiographyDay 1, 3, 7, 30 and 12 month after PCIEchocardiographic index includes WMSI and LVEF
TIMI Flow Grade (TFG)One mins after PCITIMI Flow Grade (TFG)assesses flow in the epicardial arteries
TIMI Myocardial Perfusion Grade (TMPG)One mins after PCITMPG is an angiographic measure of myocardial perfusion
TIMI Myocardial Perfusion Frame Count (TMPFC)One mins after PCITMPFC is a novel method to standardize and quantify myocardial perfusion by timing the filling and washout of contrast in the myocardium using cine-angiographic frame-counting. Briefly, the first frame of TMPFC was defined as the frame that clearly demonstrated the first appearance of myocardial blush beyond the IRA (F1). The last frame of TMPFC was then defined as the frame where contrast or myocardial blush disappeared (F2). TMPFC is F2-F1 frame counts at a filming rate of 15 frames/sec, or (F2-F1)×2 frame counts at the corrected filming rate of 30 frames/sec
CMR imagingDay 1, 3, 7, 30 and 12 month after PCICMR imaging will be collected using a 3.0-Tesla-scanner (Achieva, Philips Healthcare, The Netherlands) under electrocardiogram-triggered gating in School Shanghai Jiaotong University school of medicine RenJi hospital.
TIMI Frame Count (CTFC)One mins after PCICTFC is a continuous measurement assessing flow in the epicardial arteries.

Other

MeasureTime frameDescription
hemodynamic adverse related to rhBNP72 hour since rhBNP administrationlow perfusion sign, and Noninvasive systolic blood pressure is below 90mmHg with or without diastolic blood pressure below 60mmHg, Excluding other reason.

Countries

China

Contacts

Primary ContactJun Pu, MD,PhD
pujun310@hotmail.com86-21-68383477

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026